羟氯喹对银屑病的影响:系统综述及COVID-19治疗警示
该系统综述检索Embase和MEDLINE,纳入15篇文章共18例患者,分析羟氯喹(HCQ)治疗后银屑病新发、加重或复发的情况。结果显示HCQ可能诱导、加重或复发银屑病,女性占多数(77.8%),半数患者无银屑病史,提示需监测HCQ的皮肤不良反应。
要点
- HCQ治疗可能诱导、加重或复发银屑病。
- 女性病例占比显著高于男性(77.8% vs 11.1%)。
- 50%的患者在用药前无银屑病史。
核心结论
- HCQ治疗可能导致银屑病新发、加重或复发。
研究设计与样本
- 系统综述,检索Embase和MEDLINE,纳入15篇文章共18例患者。
主要发现
- 18例中9例(50.0%)为新发银屑病,5例(27.8%)为银屑病症状加重,4例(22.2%)为银屑病复发。
- 女性病例14例(77.8%),男性2例(11.1%),性别未报告2例(11.1%)。
- 9例(50%)患者在服用HCQ前无银屑病史。
临床怎么用
- 使用HCQ治疗时需监测银屑病相关皮肤不良反应。
局限性
- 需临床试验进一步明确HCQ在COVID-19患者中的安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While evidence suggests that hydroxychloroquine (HCQ) may decrease the viral load in patients with a COVID-19 infection, a number of case reports indicate adverse dermatologic effects of this potential treatment. OBJECTIVE: To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment. METHODS: Embase and MEDLINE were comprehensively searched for original studies examining adverse effects of HCQ treatment related to psoriasis. Participant demographics and details of HCQ administration and psoriasis diagnosis were extracted from 15 articles representing 18 patients. RESULTS: Women accounted for a significantly larger number of cases of psoriasis compared with men and unreported sex (14 [77.8%] vs 2 [11.1%] vs 2 [11.1%], respectively). In addition, 50% (n = 9) of the patients did not have a history of psoriasis before taking HCQ. Of the 18 patients, 9 (50.0%) experienced de novo psoriasis, 5 (27.8%) experienced exacerbation of psoriatic symptoms, and 4 (22.2%) had a relapse of psoriasis after HCQ administration. CONCLUSION: HCQ treatment may result in induction, exacerbation, or relapse of psoriasis. Monitoring for adverse effects of HCQ treatment is necessary, and clinical trials are essential in characterizing the safety profile of HCQ use in patients with a COVID-19 infection.
引用
- Sachdeva M, Mufti A, Maliyar K, et al. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. J Am Acad Dermatol. 2020. PMID: 32442699. doi:10.1016/j.jaad.2020.05.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。